Related Experiment Video
Updated: Nov 6, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.7K
Regional Variation in Treatment for Highest-Risk Patients With Non-Small Cell Lung Cancer
Katherine J Bick1, Li Ding2, Peggy J Ebner1
1Division of Thoracic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
The Annals of Thoracic Surgery
|May 8, 2021
Summary
Socioeconomic disparities in non-small cell lung cancer treatment and survival are regionally varied. Targeted regional interventions are needed to address these disparities for high-risk patients.
Area of Science:
- Oncology
- Health Services Research
- Health Disparities
Background:
- Non-small cell lung cancer (NSCLC) patients with multiple high-risk socioeconomic factors face significant treatment and survival disparities.
- These disparities may differ based on geographic region within the United States.
Purpose of the Study:
- To investigate regional variations in treatment and survival disparities among NSCLC patients with three or more high-risk socioeconomic factors.
Main Methods:
- Utilized the National Cancer Database (2010-2015) for clinical stage I-IIA NSCLC patients.
- Categorized patients into standard, nonstandard, or no curative treatment groups.
- Employed multivariable logistic regression and Cox proportional hazards regression for regional treatment and survival analyses.
Main Results:
- Significant regional differences in nonstandard treatment and no curative treatment were observed compared to New England.
- West North Central showed the highest odds of nonstandard treatment (OR 2.09) and all-cause mortality (HR 1.10).
- West South Central had the highest odds of no curative treatment (OR 3.56), and Mountain region had the shortest 5-year survival (36.8%).
Conclusions:
- NSCLC patients with multiple high-risk socioeconomic factors experience significant, regionally varying treatment and survival disparities.
- Disparities are most pronounced in specific regions, necessitating tailored regional interventions.
- Addressing these disparities can improve outcomes for the highest-risk NSCLC patient populations.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:50Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K